Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis. Thirty‐one patients were included. The Ankylosing S...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiaoliang, Zhu, Ruifang, Wu, Jian, Xue, Ling, Gu, Meihua, Miao, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214645/
https://www.ncbi.nlm.nih.gov/pubmed/31961477
http://dx.doi.org/10.1111/cts.12738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214645/
https://www.ncbi.nlm.nih.gov/pubmed/31961477
http://dx.doi.org/10.1111/cts.12738

Ejemplares similares